EUCTR2005-001533-15-CZ进行中（未招募）1 期
A Randomised, Double-Blind, Two-Period Study to Evaluate the Safety and Efficacy of Etanercept on Skin and Joint Disease in Psoriasis Subjects with Psoriatic Arthritis - PRESTA
Global Medical Affairs, Wyeth Research Division of Wyeth Pharmaceuticals Inc0 个研究点目标入组 800 人开始时间: 2006年11月10日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •These are main inclusion criteria. Please refer to the protocol for the complete list.
- •1. 18 years of age or older at time of consent.
- •2. Active PsA defined by the following criteria:
- •- 2 swollen joints and 2 tender/painful joints for at least 3 months at screening and baseline, or
- •- Sacroiliitis or spondylitis in at least 1 joint documented by radiograph
- •- Negative serum rheumatoid factor (within 6 months of screening)
- •Note: A rheumatologist should establish the diagnosis of PsA if possible. Radiographs of the hands, feet, or lumbar spine/pelvis may be used to help establish the diagnosis.
- •3. Clinically stable, plaque psoriasis involving at least 10% body surface area (BSA) and PGA of Psoriasis status of moderate or worse (moderate, marked, or severe) at screening and baseline.
- •4. Negative serum pregnancy test taken at screening in all women except those who were surgically sterile or at least 1 year postmenopausal. Sexually active women of childbearing potential participating in the study must use a medically acceptable form of contraception (which include oral contraception, injectable or implantable methods, intrauterine devices, or properly used barrier contraception). A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant. This includes women who are using contraceptives or whose sexual partners are either sterile or using contraceptives
- •5. Agreement by male subjects who are not surgically sterile and female subjects who are not surgically sterile or postmenopausal to use reliable methods of birth control for the duration of the study.
- •6. Ability to self-inject drug or have a designee who can do so.
- •7. Capable of understanding and willing to provide signed and dated written voluntary informed consent before any protocol specific procedures are performed.
- •8. Ability to store injectable test article at 2 C to 8 C.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •These are main inclusion criteria. Please refer to the protocol for the complete list.
- •1. Evidence of skin conditions (eg, eczema) other than psoriasis that would interfere with evaluations of the effect of study medication on psoriasis.
- •2. Psoralen plus ultraviolet A radiation (PUVA), cyclosporine, alefacept (Amevive™), efalizumab (Raptiva™), anakinra (Kineret™) or any other systemic anti-psoriasis therapy within 28 days study drug initiation (Exception: methotrexate [MTX] and acitretin - see concomitant treatment section of protocol).
- •3. Ultraviolet B radiation (UVB) therapy, topical steroids, topical Vitamin A or D analog preparations, or anthralin within 14 days of study drug initiation (exception: topical steroids at no higher than moderate strength, are permitted on scalp, axillae, and groin but dose and formulation must remain stable throughout study).
- •4. Prior exposure to any TNF-inhibitor, including etanercept.
- •5. Corticosteroid dose of prednisone >10 mg/day (or equivalent) or change in dose within 28 days of baseline.
- •6. Receipt of intra-articular, intravenous, intramuscular, or subcutaneous corticosteroid injection within 28 days of screening and during the study.
- •7. Dose of NSAID changed within 14 days of baseline.
- •8. Hot, red, joint not evaluated by a rheumatologist as PsA.
- •9. Abnormality in haematology or chemistry profiles: haemoglobin nmt 85 g/L; haematocrit nmt 27%; platelet count nmt 125 x 10 power 9 /L; white blood cell count nmt 3.5 x 10 power 9 /L; serum creatinine nlt 175 mmol/L; aspartate aminotransferase (AST [SGOT]) and alanine aminotransferase (ALT [SGPT]) nlt 2 times the laboratory’s upper limit of normal.
- •10. Significant concurrent medical events including:
- •·Uncontrolled hypertension (defined as screening systolic blood pressure > 160 mm Hg or screening diastolic blood pressure > 100 mm Hg)
- •·Myocardial infarction within 12 months of the screening visit
- •·Unstable angina pectoris
- •·Class III or IV congestive heart failure as defined by the New York Heart Association or uncompensated congestive heart failure (Hunt 2001)
- •·Severe pulmonary disease requiring hospitalisation or supplemental oxygen
- •·Diagnosis of multiple sclerosis or other central demyelinating diseases
- •·Presence or history of confirmed blood dyscrasias
- •·Uncontrolled diabetes mellitus
- •·Rheumatoid arthritis, systemic lupus erythematosus, gout, scleroderma, or polymyositis
- •·Cancer or history of cancer
- •·Serious infection (infection associated with hospitalisation and/or intravenous antibiotics) within 1 month of test article administration or active infection at screening
- •·Open cutaneous ulcers
- •·Known human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) positive
- •·Tuberculosis (TB) infection (Note: follow local country guidelines for appropriate screening and treatment of tuberculosis in the setting of anti-TNF therapy)
- •·Any condition that, in the investigator’s judgment, might cause this study to be detrimental to the subject
- •11. Receipt of any live (attenuated) vaccine within 4 weeks prior to baseline.
- •12. Known contraindication or hypersensitivity to etanercept or its excipients.
- •13. Pregnant or breast-feeding women.
- •14. Reasonable expectation that the subject will not be able to satisfactorily complete the study.
- •15. History of or current psychiatric illness that would interfere with the subject’s ability to comply with protocol requirements or give informed consent.
- •16. History of al
研究者
相似试验
进行中（未招募）
不适用
A Randomised, Double-Blind, Two-Period Study to Evaluate the Safety and Efficacy of Etanercept on Skin and Joint Disease in Psoriasis Subjects with Psoriatic Arthritis - PRESTAPsoriasis Subjects with Psoriatic ArthritisEUCTR2005-001533-15-DEGlobal Medical Affairs, Wyeth Research Division of Wyeth Pharmaceuticals Inc800
进行中（未招募）
1 期
A Randomised, Double-Blind, Two-Period Study to Evaluate the Safety and Efficacy of Etanercept on Skin and Joint Disease in Psoriasis Subjects with Psoriatic Arthritis - PRESTAEUCTR2005-001533-15-ESGlobal Medical Affairs, Wyeth Research Division of Wyeth Pharmaceuticals Inc800
进行中（未招募）
不适用
A Randomised, Double-Blind, Two-Period Study to Evaluate the Safety and Efficacy of Etanercept on Skin and Joint Disease in Psoriasis Subjects with Psoriatic Arthritis - PRESTAPsoriasis Subjects with Psoriatic ArthritisEUCTR2005-001533-15-ATGlobal Medical Affairs, Wyeth Research Division of Wyeth Pharmaceuticals Inc800
进行中（未招募）
1 期
A Randomised, Double-Blind, Two-Period Study to Evaluate the Safety and Efficacy of Etanercept on Skin and Joint Disease in Psoriasis Subjects with Psoriatic Arthritis - PRESTAEUCTR2005-001533-15-GRGlobal Medical Affairs, Wyeth Research Division of Wyeth Pharmaceuticals Inc800
进行中（未招募）
不适用
A Randomised, Double-Blind, Two-Period Study to Evaluate the Safety and Efficacy of Etanercept on Skin and Joint Disease in Psoriasis Subjects with Psoriatic Arthritis - PRESTAEUCTR2005-001533-15-PTGlobal Medical Affairs, Wyeth Research Division of Wyeth Pharmaceuticals Inc800